Ibalizumab (Trogarzo)

All References

• Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019 63. pii: e00110-19.
  [PubMed Abstract]
• Bettiker RL, Koren DE, Jacobson JM. Ibalizumab. Curr Opin HIV AIDS. 2018;13:354-8.
  [PubMed Abstract]
• Dimitrov A. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr Opin Investig Drugs. 2007;8:653-61.
  [PubMed Abstract]
• Emu B, DeJesus E, Berhe M, et al. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311). Open Forum Infect Dis. 2019 Oct; 6(Suppl 2): S303.
  [Open Forum Infectious Diseases]
• Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379:645-54.
  [PubMed Abstract]
• Iacob SA, Iacob DG. Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy. Front Microbiol. 2017;8:2323.
  [PubMed Abstract]
• Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53:450-7.
  [PubMed Abstract]
• Lewis S, Fessel J, Emu B, et al. Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24 week study. Conference on Retroviruses and Opportunistic Infections 2017; Seattle, WA. Abstract 449LB.
  [CROI]
• Sheikh V, Murray JS, Sherwat A. Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty. N Engl J Med. 2018;379:605-607.
  [PubMed Abstract]
• Toma J, Weinheimer SP, Stawiski E, et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011;85:3872-80.
  [PubMed Abstract]